Angina Pectoris Treatment Market Size, Share and Global Trend By Drug Class (Beta Blockers, Calcium Antagonists, Anti-coagulants, Anti-Platelets), Disease Type (Stable or chronic angina, Unstable angina, Variant and microvascular angina), Distribution Channel (Online pharmacies, Hospital pharmacies, Retail pharmacies) and Regional Forecast, 2024-2032

Angina Pectoris in a medical term is defined as the chest pain that occurs due to coronary heart disease. When the heart muscles are unable to receive a sufficient amount of blood and the heart’s arteries get blocked that leads to discomfort or squeezing pain in the chest leading to angina pectoris or ischemia. Angina can be classified as stable angina which is caused by physical exertion unstable angina arises due to the obesity which results in the deposition of fats in the arteries of heat leading to the blockage of blood vessels.

In case of Prinzmetal's angina, the spam in coronary arteries leads to narrowing of the vessels leading to the reduction of blood flow. Increasing prevalence of coronary heart disease and growing geriatric patient population is likely to enhance the growth Angina Pectoris Market. According to the reports published by Annals of Translational Medicine Journal around 15.5 million people who aged 20 years or more within the U.S. suffered from coronary heart disease in 2016. 

The growing awareness about available therapy options, the upcoming pipeline of potential pipeline candidates, surge in the economies along with rising per capita healthcare spending along with personalized medicine are the major factors that are driving the angina pectoris market. In March 2019, Baxter got approval from U.S. FDA to launch the ready to use eptifibatide, a platelet aggregation inhibitor, that will prevent blood from coagulation, increase the supply of blood to the heart, and will eventually prevent coronary heart disease. In 2015, Corlanor was launched by Amgen Inc. received FDA approval which was used to treat chronic heart failure.

But on the contrary, due to the high expenditure in the treatment of angina pectoris and lack of effective and affordable diagnostic methods is expected to reduce the growth in angina pectoris treatment market.

Key Players Covered:

Major companies involved in the global angina pectoris treatment drug market include Abbott., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc., Sanofi, and other key players.

SEGMENTATION

The quick onset of action and accessibility to large pool patients can be considered as the major factors accounting for the growth of beta-adrenergic blockers.

Key Insights: 

• Patent analysis
• Overview of innovative pipeline drugs
• Emerging guidelines for treatment
• The Regulatory scenario for key countries/regions
• Key Developments- mergers, acquisitions, and partnerships

Regional Analysis:

Geographically, the global angina pectoris treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Amongst them, North America is likely to dominate the angina pectoris treatment market during the projected period owing to the emerging guidelines involved in diagnosis and management of Patients With Stable Ischemic Heart Disease and new product launches. In October 2018, Janssen Pharmaceuticals, Inc. launched Xarelto (rivaroxaban) which was approved by FDA which along with beta-blockers, nitrates, calcium channel blockers, and ACE inhibitors can be used to treat chronic angina. In February 2019, Lupin Pharmaceuticals, Inc. launched Ranolazine extended-release tablets in the US that will be used in the treatment of chronic angina. The Asia Pacific is also considered to be the next to the fastest growing region for the global angina market owing to the increase of economics in the healthcare sector.

Key Industry Developments

• In October 2018, Xarelto (rivaroxaban) was approved by FDA which along with beta-blockers, nitrates, calcium channel blockers and ACE inhibitors can be used to treat chronic angina.
• In May 2017, AstraZeneca in collaboration with Recordati S.p.A together was involved in marketing Metoprolol succinate, a beta blocker which is used to treat angina pectoris.